- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04767620
Clinical Trial of Ruxian Zengsheng No. 1 Decoction
February 21, 2021 updated by: Jiuda Zhao
A Prospective, Open, Randomized, Controlled Phase Ⅱ Clinical Study of Ruxian Zengsheng No. 1 Decoction in Treating Liver-stagnation and Qi-stagnation Hyperplasia of Breast
A prospective, open, randomized, controlled phase II clinical study is planned to clarify the efficacy and related adverse reactions of Mammary Glandular Hyperplasia No. 1 Decoction in the treatment of liver-qi stagnation type breast hyperplasia, relieve the pain of patients with breast hyperplasia, and improve the quality of life of patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
- This study is a prospective, open, randomized, controlled Phase II clinical study. Strictly follow the design requirements of the clinical research, randomly enroll patients, control each link of the study with high quality, and obtain objective research results to improve the evidence-based medicine evidence of the breast hyperplasia treatment of liver-stagnation and qi stagnation type breast hyperplasia with Rugongshengsheng No.1 prescription;
- Recruiting 137 patients with liver-stagnation and qi stagnation type breast hyperplasia through the Breast Center Clinic of the Affiliated Hospital of Qinghai University (see the inclusion criteria for details) (see the research plan for the specific calculation method), and randomly divided into 91 cases according to the 2:1 random number method Group, 46 cases of control group. The research group was treated with No.1 Rugdenzengsheng prescription for a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The control group was given observation treatment and follow-up in outpatient clinic. All patients will be followed up by telephone or outpatient by a dedicated person, and the results of the follow-up will be recorded objectively;
- Specific treatment plan: The study group was treated with Mammary gland Hyperplasia No. 1 orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, Beibuihu 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control;
- All patients will be followed up by telephone or on-site within one week after treatment. The evaluation criteria are detailed in the attached table. The curative effect evaluation standard of hyperplasia of mammary glands is mainly through the scoring method. The analgesic curative effect standard (NRS score on the most painful day): clinical recovery: the pain disappears completely; marked effect: the pain is significantly reduced, only occasional pain or only slight tenderness; effective : Pain is reduced or tenderness is reduced; Ineffective: Pain remains unchanged or worsened. In addition, collect clinical pathological data of patients, such as age, gender, reproductive history, menstrual history, family history, breastfeeding history, etc.;
- Secondary efficacy indicators: safety evaluation, safety endpoints include the incidence of adverse events and adverse reactions, liver function, renal function and urine routine laboratory examinations before and after treatment;
- Apply for ethical review by the ethics committee of the Affiliated Hospital of Qinghai University, and conduct research in strict accordance with the ethical requirements of the ethics committee of the Affiliated Hospital of Qinghai University.
Study Type
Interventional
Enrollment (Anticipated)
137
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Xining, Qinghai
-
Qinghai, Xining, Qinghai, China, 810000
- Recruiting
- Qinghai University Affiliated Hospital
-
Contact:
- Zhao Jiuda, MD
- Phone Number: 13327661976
- Email: jiudazhao@126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Healthy women over 18 years of age;
- Patients who meet the diagnostic criteria for breast color Doppler ultrasound diagnosis of breast hyperplasia and the course of disease exceeds 3 months;
- Meet the syndrome differentiation criteria for liver-stagnation and qi stagnation (main symptoms are ① breast distension Pain and pain; ② breast pain and/or lumps are related to menstruation and mood changes; ③ irritability and irritability; ④ flank fullness. Secondary symptoms: ① the lumps are single, soft and tender; ② Young women; ③Irregular menstruation or dysmenorrhea; ④Pale red tongue, thin white or thin yellow coating, stringy pulse. With 3 main symptoms or 2 main symptoms + 2 secondary symptoms);
- breast color ultrasound, breast molybdenum Target, or breast MRI showed BI-RADS 2-3;
- NRS (0-10 pain rating) score ≥ 4 points on the most painful day before treatment, according to the score, the pain is divided into mild 3 points, moderate Grade 4-6 points, severe 7-10 points;
- Voluntarily participate in the clinical study and sign the informed consent form after the informed consent (patients voluntarily accept the study and sign the informed consent).
Exclusion Criteria:
- Patients with other breast diseases or other causes of breast pain (such as mastitis, breast cancer, etc.);
- Patients with severe cardiovascular and cerebrovascular diseases, liver, kidney, malignant tumors, blood system diseases, and Patients with mental illness;
- Patients who have been confirmed to have dysfunctional uterine bleeding, amenorrhea, polycystic ovary syndrome, menopausal syndrome and hyperprolactinemia before treatment, still need to regulate hormone levels for treatment;
- Patients diagnosed with hypercortisolism before treatment still need bromocriptine treatment;
- Menstrual period is more than 7 days, menopause and severe irregular menstrual cycle;
- ALT, AST, ALP, TBIL , GGT is higher than the upper limit of normal; or abnormal blood, urine, electrocardiogram and other examination items;
- pregnant or breastfeeding women, or patients with pregnancy plans in the next six months;
- 1 before treatment Use Chinese or Western medicine to treat breast hyperplasia (including painkillers, topical drugs, acupuncture, etc.) within the month and during the treatment period, and use hormonal drugs (except for long-term use), and oral contraceptives within six months;
- People who are known to be allergic to the ingredients of the test drug prescription;
- Past alcohol or drug abuse history;
- Patients who participated in other clinical studies within 3 months before enrollment;
- According to the judgment of the researchers, there are other diseases Or circumstances will reduce the possibility of enrollment or complicate enrollment. For example, frequent changes in the work environment may cause loss to follow-up, and patients with mental and behavioral disorders, or the inability to sign informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: study groups
The study group was treated with Rugdenzengsheng No. 1 prescription for 2 courses.
|
The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period.
The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g.
Method of administration: 14 doses in total, taken twice a day.
The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
Other Names:
|
No Intervention: control groups
The control group was treated with observational treatment and follow-up in outpatient clinic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief Rate of Mammary Gland Pain
Time Frame: 12 weeks
|
To clarify the effectiveness of Rugshengsheng No.1 Recipe in the Affiliated Hospital of Qinghai University in reducing the pain of patients with liver-stagnation and qi stagnation type breast hyperplasia, as well as related adverse side effects, and provide reliable clinical evidence for further clinical promotion
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relief time of breast pain
Time Frame: 12 weeks
|
Related Adverse Reactions of Rugongshengsheng No.1 Prescription
|
12 weeks
|
Related adverse reactions
Time Frame: 12 weeks
|
Statistic about the related adverse reactions of patients after taking the No.1 Recipe for Mammary Gland Growth, the degree and severity of the adverse reactions
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2021
Primary Completion (Anticipated)
December 31, 2021
Study Completion (Anticipated)
December 31, 2021
Study Registration Dates
First Submitted
February 9, 2021
First Submitted That Met QC Criteria
February 21, 2021
First Posted (Actual)
February 23, 2021
Study Record Updates
Last Update Posted (Actual)
February 23, 2021
Last Update Submitted That Met QC Criteria
February 21, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AHQU-2021002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mammary Gland Hyperplasia
-
Vastra Gotaland RegionRecruiting
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Not yet recruitingBreast Cancer | Neoplasm, Breast | Malignant Neoplasm of Breast | Breast Tumor | Mammary Cancer | Mammary Neoplasms, Human | Tumor, Breast | Mammary NeoplasmUnited States
-
Indiana UniversityNational Cancer Institute (NCI); Indiana University Health; Eskenazi HealthActive, not recruitingBreast Cancer | Anxiety | Breast Neoplasm | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Mammary Neoplasms, Human | Human Mammary Carcinoma | Mammary Carcinoma, HumanUnited States
-
Tianjin Medical University Cancer Institute and...RecruitingMammary Neoplasms, HumanChina
-
University of Sao PauloCompletedPeriodontal Diseases | Chemotherapy Effect | Mammary Neoplasm, Human
-
Indiana UniversityIndiana University HealthCompletedBreast Cancer | Breast Neoplasms | Anxiety | Breast Carcinoma | Fear | Cancer of Breast | Malignant Tumor of Breast | Malignant Neoplasm of Breast | Mammary Cancer | Human Mammary Carcinoma | Mammary Neoplasm, Human | Mammary Carcinoma | Neoplasm Remission, Spontaneous | Spontaneous Neoplasm Regression | Regression,... and other conditionsUnited States
-
Sonya ReidSusan G. Komen Breast Cancer Foundation; AgendiaRecruitingMetastatic Breast Cancer | Invasive Mammary CarcinomaUnited States
-
Pontificia Universidad Catolica de ChileComisión Nacional de Investigación Científica y TecnológicaRecruitingBreast Cancer | Breast Tumor | Mammary Cancer | Mammary TumorChile
-
University Hospital, LilleInstitut National de la Santé Et de la Recherche Médicale, France; Galderma...RecruitingPaget Disease, Extramammary | Paget Disease of the VulvaFrance
-
Johann Wolfgang Goethe University HospitalKlinikum LudwigshafenCompletedComplications Due to Coronary Artery Bypass Graft | Injury of Internal Mammary ArteryGermany
Clinical Trials on Rugdenzengsheng No. 1 prescription
-
American Academy of Family PhysiciansTerminatedOsteoarthritis | Gastroesophageal Reflux DiseaseUnited States
-
Guangzhou University of Chinese MedicineFirst Affiliated Hospital, Sun Yat-Sen University; Shanghai 10th People's Hospital and other collaboratorsCompletedAcute Coronary Syndrome | Percutaneous Coronary Artery Intervention | Coronary Artery Bypass Graft
-
Zhu MingjunUnknownIschemic Heart FailureChina
-
Centre Hospitalier Universitaire DijonCompletedCommunity InfectionsFrance
-
University of Colorado, DenverNational Institute on Drug Abuse (NIDA)Completed
-
Henri Mondor University HospitalUnknownRespiratory Tract InfectionsFrance
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationCompletedUrinary Tract Infections | Upper Respiratory Tract InfectionsSwitzerland
-
Penn State UniversityPronova BioPharmaCompletedInflammatory ResponsesUnited States
-
CENTOGENE GmbH RostockShire Human Genetic Therapies, Inc.CompletedCerebrovascular AccidentAustria, Belgium, Croatia, Finland, France, Georgia, Germany, Ireland, Italy, Malta, Poland, Portugal, Spain, United Kingdom
-
Johns Hopkins UniversityTerminatedBariatric SurgeryUnited States